Andrew J. Armstrong, MD

Articles

Dr. Armstrong on the utility of PARP Inhibitors in Mutated Prostate Cancer

April 30th 2020

Andrew J. Armstrong, MD, discusses the utility of PARP inhibitors in mutated prostate cancer.

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

April 10th 2020

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

Dr. Armstrong on Detection of Chromosomal Defects in mCRPC

March 21st 2020

Andrew J. Armstrong, MD, discusses the use of circulating tumor cell to detect chromosomal instability in men with metastatic castration-resistant prostate cancer.

Dr. Armstrong on the Utility of AR-V7 as a Biomarker in Prostate Cancer

March 20th 2020

Andrew J. Armstrong, MD, discusses the utility of AR-V7 as a biomarker in prostate cancer.

Dr. Armstrong on the Utility of Liquid Biopsies in mCRPC

March 5th 2020

Andrew J. Armstrong, MD, discusses the utility of liquid biopsies in metastatic castration-resistant prostate cancer.

Dr. Armstrong on AR-V7 as a Biomarker of Response to Taxane Chemotherapy in mCRPC

February 25th 2020

Andrew J. Armstrong, MD, professor of medicine, associate professor in pharmacology and cancer biology, and professor in surgery at Duke University School of Medicine and a member of the Duke Cancer Institute, discusses the potential of AR-V7 as a predictive biomarker of response to taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Armstrong Discusses Findings of ARCHES Trial in Prostate Cancer

April 2nd 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses findings from the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Dr. Armstrong Discusses ARCHES Trial in Prostate Cancer

March 1st 2019

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the ARCHES trial in patients with metastatic hormone-sensitive prostate cancer.

Dr. Armstrong on Sipuleucel-T in Prostate Cancer

December 7th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses sipuleucel-T (Provenge) for patients with prostate cancer.

x